Videos

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

This Savvy Stories episode of the Skin of Color Savvy podcast features 4 speakers highlighting the SOCS Clinical Investigators Training Program.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

In this interview at EADV, Bernstein highlights dupilumab’s impact on urticaria activity in individuals with chronic spontaneous urticaria (CSU).

If this connection is proven, the gut microbiome may present an entirely new pathway for treatment and prevention of heart failure.

This discussion highlights 24-week findings on povorcitinib for those with moderate to severe hidradenitis suppurativa (HS).

Rubin reflects on the FDA approval of a SC induction regimen for guselkumab (Tremfya) in UC and explains the significance of having both IV and SC induction options in IBD.

This EADV 2025 interview featuring Linda Stein Gold, MD, highlights her team’s findings on icotrokinra versus placebo and versus deucravacitinib in psoriasis.

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

Neuen describes varying treatment effects with 4 different classes of IgAN therapeutics and future opportunities for personalized treatment.

This episode highlights the results of the ATTAIN-1 and STEP UP clinical trials, examining the potential of their respective GLP-1 RA subjects.

This interview highlighted findings on actinic keratosis following treatment with tirbanibulin.

Staller describes unmet needs in gastroparesis and key recommendations for its diagnosis and management from the new AGA guidelines.

This Sickle Cell Awareness Month, HCPLive draws attention to recent advancements made in SCD treatment and how much still needs to be done to address it.

This September 22 Savvy Conversations episode features a conversation on vitiligo and its impact on patients of diverse skin types.

Neuen reviews recent advances in IgAN treatment and findings from a systematic review and meta-analysis guiding their use in clinical practice.

A significant amount of TED cases go undiagnosed due to a lack of routine screening – Khachikian discusses what is needed to address this problem.

New data reveals ritlecitinib's long-term efficacy for alopecia areata, showing sustained hair regrowth in 30% of patients after 3 years.

In this interview at EADV, Hong speaks about his team’s findings on IL-22RA1 antagonism with temtokibart and its impact on atopic dermatitis.

Adolescents with alopecia areata show promising treatment responses, highlighting the need for diverse therapeutic options to improve outcomes.

This interview segment with Bunick at EADV highlights some of the significance of these recent findings on cardiovascular risk and upadacitinib use over 6 years.

Chapman discussed further research to be done with PDT for basal cell carcinoma.

In this EADV interview, Bunick touches on his team’s findings related to risk of VTE, MACE, and malignancy in patients with atopic dermatitis treated with upadacitinib for 6 years.

Janovsky describes the importance of early identification, the new treatment options available for MASH, and the continued importance of diet and exercise.

Le describes growing multidisciplinary conversations around CKM and why cardiovascular health needs to be a central focus of MASH/MASLD care.

This EADV interview featured a discussion with Brittany Craiglow, MD, on the topic of developments in the field of alopecia areata treatment.

In this EADV interview, Chovatiya highlights some of his session’s most notable takeaways regarding current treatments and new data in the atopic dermatitis space.